IDRSF - Idorsia: Aprocitentan Approval Is A Vital News

2024-03-22 11:49:09 ET

Summary

• Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns.
• FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales of over $2 billion.
• Despite positive developments, caution remains due to slow QUVIVIQ sales and the need for additional cost savings.

Here at the Lab, following the exciting news on Idorsia ( IDRSF ), we are back to comment on the company equity story. Idorsia is a Switzerland-based biopharmaceutical player specializing in small molecule discovery. The company has a diverse pipeline and targets several diseases, including chronic insomnia, systemic lupus erythematosus, and resistant hypertension....

For further details see: